Needham Hikes Centessa (CNTA) PT to $38 on High Potential for ORX-750 Trial Success and M&A Appeal
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks to buy according to Wall Street. On January 5, Needham raised the firm’s price target on Centessa to $38 from $35 with a Buy rating on the shares. Needham suggested that Centessa’s stock momentum is poised to persist through 2026 due to the forthcoming data from the dose-escalation cohorts of the ongoing ORX-750 Phase 2a study. Consequently, the firm identified the company as one of the most compelling acquisition targets within the biotech sector for the coming year.
Furthermore, on December 10, Oppenheimer assumed coverage of Centessa with an Outperform rating with a price target of $62, which was brought up from $40. The firm has been designated a top pick by Oppenheimer, largely due to its pipeline of potentially best-in-class orexin agonists. Oppenheimer anticipates a commercial launch in H1 2028, projecting that these treatments will dramatically broaden the narcolepsy market by improving diagnosis rates, patient uptake, compliance, and pricing power relative to existing therapies. Believing that the company is currently significantly undervalued, the firm expects substantial stock appreciation driven by multiple clinical data readouts scheduled throughout 2026 and the following years.
In Q3 2025, Centessa Pharmaceuticals confirmed that its lead candidate, ORX750, showed potential best-in-class efficacy for treating Narcolepsy Type 1 (NT1), Type 2 (NT2), and Idiopathic Hypersomnia. Phase 2a data showed that low doses of the oral OX2R agonist achieved statistically significant, dose-dependent normalization of wakefulness. Centessa Pharmaceuticals (NASDAQ:CNTA) is now prepared for a major clinical expansion in Q1 2026. During this period, the company expects to launch the ORX750 registrational program, initiate patient studies for the highly potent ORX142, and begin first-in-human trials for ORX489, its most potent agonist to date.
Centessa Pharmaceuticals (NASDAQ:CNTA) is a clinical-stage pharmaceutical company that discovers, develops, and delivers medicines.
While we acknowledge the potential of CNTA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Content Original Link:
" target="_blank">
